Eldorado Hotel & Spa Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2004



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Angiogenesis: Novel Basic Science Insights and Human Therapy (A5)


Organizer(s) Napoleone Ferrara, Shahin Rafii and Elisabetta Dejana
January 13—18, 2004
Eldorado Hotel & Spa • Santa Fe, New Mexico USA
Abstract Deadline: Sep 22, 2003
Late Abstract Deadline:
Scholarship Deadline:
Early Registration Deadline: Nov 13, 2003

Sponsored by Abbott Laboratories and Berlex Biosciences

Summary of Meeting:
The establishment of a blood supply has been long known to be of fundamental importance for embryonic development, reproductive functions, tumorigenesis and many other proliferative processes. Over the last decade, major progress has been made in the identification of some key angiogenic inducers and several anti-angiogenic molecules. Substantial advances have been also made in the understanding of the regulation of angiogenesis by oxygen tension and other mechanisms. However, many important questions are still unanswered. For example, the traditional concept that angiogenesis occurs by sprouting of resident endothelial cells has been complemented by the finding that bone marrow-derived progenitor cells can be incorporated in the vessels, but the contribution of these elements in various pathophysiologic situations remains to be determined. Also, the identification of at least one tissue-specific angiogenic factor suggests a greater level of complexity and specialization than previously appreciated. An issue intensely debated in the field is the interplay and cooperation among soluble factors and extracellular matrix proteins to achieve not only morphogenesis but also diversity among blood vessels in different organs. In addition, clinical testing of angiogenesis inducers and inhibitors is in advanced stage and results of some pivotal trials will be known by the time the meeting takes place. The objective of this meeting is to discuss the latest basic science findings and review the status of the clinical application of angiogenic growth factors and inhibitors; learn the latest molecular and genetic findings on the regulation of angiogenesis; acquire an integrated view of the role of blood vessels in health and disease; discuss the results of then initial pivotal clinical trials in angiogenesis and anti-angiogenesis; and identify the pathological conditions that are most likely to benefit from such treatments.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


TUESDAY, JANUARY 13

15:00—19:00
Registration

Foyer
18:15—19:15
Refreshments

Court
19:15—19:30
Orientation

Ballroom
19:30—21:30
Keynote Session
Meeting has ended...abstracts no longer viewable online.

Ballroom
Kari K. Alitalo, University of Helsinki, Finland
Lymphangiogenesis: Insights to Lymphedema and Lymphatic Metastasis

William G. Kaelin, Jr., Dana-Farber Cancer Institute, USA
Molecular Pathogenesis of the Von Hippel-Lindau Hereditary Cancer Syndrome


WEDNESDAY, JANUARY 14

07:00—08:00
Breakfast

Court
08:00—11:00
Developmental Aspects of Angiogenesis
Meeting has ended...abstracts no longer viewable online.

Ballroom
* Peter F. Carmeliet, University of Leuven, VIB, Belgium
Novel Functions of VEGF

Barbara L. Hempstead, Weil Cornell Medical College, USA
Angiogenic Actions of BDNF

Anne C. Eichmann, Yale University School of Medicine, USA
Neural Receptors in Vascular Development

David J. Anderson, California Institute of Technology, USA
Neuroangiogenesis and the Control of Vessel Identity

Rong Wang, University of California, San Francisco, USA
Short Talk: Tie2-Cre-Mediated Deletion of fak Disrupts Sprouting and Intussuscepting Angiogenesis

09:20—09:40
Coffee Break

Court
11:00—13:00
Poster Setup

Sunset/Court
13:00—22:00
Poster Viewing

Sunset/Court
16:30—17:00
Coffee & Snacks Available

Court
17:00—19:15
Assembly of the Vessel Wall
Meeting has ended...abstracts no longer viewable online.

Ballroom
* Elisabetta Dejana, Uppsala University, Sweden
Intercellular Junctions and Endothelial Cell-to-Cell Signaling in Angiogenesis

Gavin O. Thurston, Regeneron Pharmaceuticals Inc., USA
Collaborative Actions of VEGFs and Angiopoietins during Normal and Pathologic Angiogenesis, and Anti-tumor Actions of the VEGF Trap

Christer Betsholtz, Uppsala University, Sweden
VEGF/PDGF Gradients and Vascular Morphogenesis

Ricky Tong, Massachusetts General Hospital, USA
Short Talk: Dynamics of Vessel Normalization following VEGF Blockade

Yasuhiro Ito, Kumamoto University, Japan
Short Talk: Angiopoietin-Related Protein 2 (ARP2) Promotes Angiogenesis but not Vascular Leakage

19:15—20:15
Social Hour

Sunset/Court
19:30—22:00
Poster Session 1

Sunset/Court

THURSDAY, JANUARY 15

07:00—08:00
Breakfast

Court
08:00—11:15
Signaling Pathways in Angiogenesis
Meeting has ended...abstracts no longer viewable online.

Ballroom
* Masabumi Shibuya, University of Tokyo, Japan
VEGF Receptor Signaling Toward Cell Growth and Survival

Carl-Henrik Heldin, Ludwig Institute for Cancer Research, Sweden
Use of PDGF Antagonists in Tumor Treatment

Jacques Pouysségur, University of Nice, France
Hypoxia Signaling and Angiogenesis

David A. Cheresh, University of California, San Diego, USA
Unexpected Role of VEGF in Ischemic Disease and Cancer

David Lyden, Weill Cornell Medical College, USA
Short Talk: Recruitment of VEGFR1+ Hematopoietic Progenitors Contributes to the Establishment of Tumor Metastasis

Steve Suchting, University of Oxford, UK
Short Talk: Robo4 is an Endothelial Specific Roundabout Receptor involved in Endothelial Cell Migration and Angiogenesis

09:20—09:40
Coffee Break

Court
11:15—13:00
Poster Setup

Sunset/Court
13:00—22:00
Poster Viewing

Sunset/Court
16:30—17:00
Coffee & Snacks Available

Court
17:00—19:15
Pathological Angiogenesis
Meeting has ended...abstracts no longer viewable online.

Ballroom
* M. Judah Folkman, Children's Hospital Boston, USA
Can the Switch to the Angiogenic Phenotype be Prevented in Human Cancer?

Robert S. Kerbel, Sunnybrook Research Institute, Canada
Molecular and Cellular Basis for the Antiangiogenic Effects of Low Dose Metronomic Chemotherapy

Michael J. Detmar, ETH - Zürich, Switzerland
Tumor Lymphangiogenesis

Hellmut G. Augustin, DKFZ & Heidelberg University, Germany
Role of EphB/ephrinB Interactions during Vascular Homeostasis and Tumor Angiogenesis

19:15—20:15
Social Hour

Sunset/Court
19:30—22:00
Poster Session 2

Sunset/Court

FRIDAY, JANUARY 16

07:00—08:00
Breakfast

Court
08:00—11:15
Microenvironment and Novel Roles of the Endothelium
Meeting has ended...abstracts no longer viewable online.

Ballroom
* Rakesh K. Jain, Massachusetts General Hospital and Harvard Medical School, USA
Angiogenesis and Lymphangiogenesis: Insights from Intravital Microscopy

Gabriele A.I. Bergers, University of Leuven, Belgium
The Microenvironment Matters: Dual Role of HIF-1a

Napoleone Ferrara, University of California, San Diego, USA
Novel Insights in the Role of VEGF and other Mediators in Endothelial Diversity

Thiennu H. Vu, University of California, San Francisco, USA
The Role of VEGF-A in Lung Development

Masataka Majima, Kitasato University School of Medicine, Japan
Short Talk: Host Stromal Prostaglandin E2-EP3 Signaling Facillitates Tumor-Associated Angiogenesis and Tumor Growth

09:20—09:40
Coffee Break

Court
11:15—13:00
Poster Setup

Sunset/Court
13:00—22:00
Poster Viewing

Sunset/Court
16:30—17:00
Coffee & Snacks Available

Court
17:00—19:00
Endothelial Progenitor and Therapeutic Aspects of Angiogenesis
Meeting has ended...abstracts no longer viewable online.

Ballroom
* Shahin Rafii, Weill Cornell Medical College, USA
Co-Recruitment of Vascular and Angio-Competent Hematopoietic Progenitor Cells Contributes to Angiogenesis

Eli Keshet, Hebrew University, Israel
Conditional Organ-Specific Induction of Vegf: Insights into Adult Neovascularization and Pro-Angiogenic Therapy

Ellen H. Filvaroff, Genentech, Inc., USA
Short Talk: VEGF Stimulates Bone Repair by Acting on Endothelial and Bone Cells

Stéphane E. Germain, INSERM, France
Short Talk: Hypoxia-Induced Gene Expression in Endothelial Cells: Identification of Angiopoietin-Like 4

19:00—20:00
Social Hour

Sunset/Court
19:30—22:00
Poster Session 3

Sunset/Court

SATURDAY, JANUARY 17

07:00—08:00
Breakfast

Court
08:00—11:00
Extracellular Matrix and Angiogenesis
Meeting has ended...abstracts no longer viewable online.

Ballroom
* Luisa Iruela-Arispe, University of California, Los Angeles, USA
Interplay Between Matrix Metalloproteases and VEGF in the Context of Tumors

Raghu Kalluri, University of Texas MD Anderson Cancer Center, USA
ECM Degradome Contributes to Novel Class of Tumor Supressors

Judith A. Varner, University of California, San Diego, USA
Integrin a4b1 Mediates Endothelial Stem Cell Trafficking during Neovascularization

Jean Plouet, Hopital Lariboisiere, France
VEGF-Driven Arterialization: A New Approach for Therapy

Shoukat Dedhar, British Columbia Cancer Research Centre, Canada
Short Talk: An Essential Role of Integrin-Linked Kinase(ILK) in Tumor Angiogenesis

09:20—09:40
Coffee Break

Court
16:30—17:00
Coffee & Snacks Available

Court
17:00—19:15
Clinical Trials
Meeting has ended...abstracts no longer viewable online.

Ballroom
* William Novotny, Genentech, Inc., USA
Clinical Development of Bevacizumab (AvastinTM, a Monoclonal Antibody to Vascular Endothelial Growth Factor) in Colorectal Cancer and Other Solid Tumors

David T. Shima, University College London, UK
VEGF Inhibition in Age-Related Macular Degeneration: Phase 2/3 Pegaptanib (Macugen™) Results

Dieter Marmé, Tumor Biology Center Freiburg, Germany
The Development of Small Molecule VEGF Receptor Inhibitors

J. Anthony Ware, Eli Lilly and Company, USA
Overview of Therapeutic Angiogenesis Clinical Trials

19:15—20:15
Social Hour

Sunset/Court
20:00—23:00
Entertainment

Sunset/Court

SUNDAY, JANUARY 18

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1R13CA105865-01




We gratefully acknowledge additional support for this conference from:


Abbott Laboratories

American Heart Association's Council on Basic Cardiovascular Sciences

Berlex Biosciences Genentech, Inc.

Abbott Laboratories
 

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676